{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:22:04Z","timestamp":1787239324909,"version":"build-2736575974"},"reference-count":65,"publisher":"Georg Thieme Verlag KG","issue":"01","funder":[{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"crossref","award":["Frontiers for the Future (FFP) Award (20\/FFP-A\/895)"],"award-info":[{"award-number":["Frontiers for the Future (FFP) Award (20\/FFP-A\/895)"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>von Willebrand disease (VWD) represents the most common inherited bleeding disorder. The majority of VWD cases are characterized by partial quantitative reductions in plasma von Willebrand factor (VWF) levels. Management of patients with mild to moderate VWF reductions in the range of 30 to 50\u2009IU\/dL poses a common clinical challenge. Some of these low VWF patients present with significant bleeding problems. In particular, heavy menstrual bleeding and postpartum hemorrhage can cause significant morbidity. Conversely, however, many individuals with mild plasma VWF:Ag reductions do not have any bleeding sequelae. In contrast to type 1 VWD, most patients with low VWF do not have detectable pathogenic VWF sequence variants, and bleeding phenotype correlates poorly with residual VWF levels. These observations suggest that low VWF is a complex disorder caused by variants in other genes beyond VWF. With respect to low VWF pathobiology, recent studies have shown that reduced VWF biosynthesis within endothelial cells likely plays a key role. However, pathological enhanced VWF clearance from plasma has also been described in approximately 20% of low VWF cases. For low VWF patients who require hemostatic treatment prior to elective procedures, tranexamic acid and desmopressin have both been shown to be efficacious. In this article, we review the current state of the art regarding low VWF. In addition, we consider how low VWF represents an entity that appears to fall between type 1 VWD on the one hand and bleeding disorders of unknown cause on the other.<\/jats:p>","DOI":"10.1055\/a-1980-8198","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T18:30:45Z","timestamp":1676917845000},"page":"044-051","source":"Crossref","is-referenced-by-count":10,"title":["Low von Willebrand Disease: A Bleeding Disorder of Unknown Cause?"],"prefix":"10.1055","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-3313","authenticated-orcid":false,"given":"James S.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland"},{"name":"National Coagulation Centre, St James's Hospital, Dublin, Ireland"},{"name":"Irish-Australian Blood Collaborative (IABC) Network, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross I.","family":"Baker","sequence":"additional","affiliation":[{"name":"Irish-Australian Blood Collaborative (IABC) Network, Dublin, Ireland"},{"name":"Western Australia Centre for Thrombosis and Haemostasis, Perth Blood Institute, Murdoch University, Perth, Australia"},{"name":"Hollywood Haemophilia Treatment Centre, Hollywood Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"issue":"21","key":"ref1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"von Willebrand's disease","volume":"375","author":"F W Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von Willebrand disease in primary care practice","volume":"8","author":"M Bowman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"M A Laffan","year":"2014","journal-title":"Br J Haematol"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"Principles of care for the diagnosis and treatment of von Willebrand disease","volume":"98","author":"G Castaman","year":"2013","journal-title":"Haematologica"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"W L Nichols","year":"2008","journal-title":"Haemophilia"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"P D James","year":"2021","journal-title":"Blood Adv"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bjh.16681","article-title":"New developments in von Willebrand disease","volume":"191","author":"H Fogarty","year":"2020","journal-title":"Br J Haematol"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1160\/TH12-04-0244","article-title":"Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease","volume":"108","author":"E M de Wee","year":"2012","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.24195","article-title":"Bleeding spectrum in children with moderate or severe von Willebrand disease: relevance of pediatric-specific bleeding","volume":"90","author":"Y V Sanders","year":"2015","journal-title":"Am J Hematol"},{"issue":"14","key":"ref10","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/bloodadvances.2018017418","article-title":"Significant gynecological bleeding in women with low von Willebrand factor levels","volume":"2","author":"M Lavin","year":"2018","journal-title":"Blood Adv"},{"issue":"13","key":"ref11","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1182\/bloodadvances.2020002081","article-title":"The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding","volume":"4","author":"L Srivaths","year":"2020","journal-title":"Blood Adv"},{"issue":"02","key":"ref12","first-page":"565","article-title":"von Willebrand disease: proposing definitions for future research","volume":"5","author":"N T Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2012.04661.x","article-title":"Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients","volume":"10","author":"G Castaman","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/hae.14078","article-title":"Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia","volume":"26","author":"P L Turecek","year":"2020","journal-title":"Haemophilia"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.blre.2012.09.002","article-title":"Hemophilic arthropathy in patients with von Willebrand disease","volume":"26","author":"K P van Galen","year":"2012","journal-title":"Blood Rev"},{"issue":"25","key":"ref16","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood.2020005843","article-title":"The relationship between ABO blood group, von Willebrand factor, and primary hemostasis","volume":"136","author":"S E Ward","year":"2020","journal-title":"Blood"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"J C Gill","year":"1987","journal-title":"Blood"},{"issue":"07","key":"ref18","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","article-title":"A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor","volume":"111","author":"L Gallinaro","year":"2008","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/asheducation-2009.1.106","article-title":"Low von Willebrand factor: sometimes a risk factor and sometimes a disease","author":"J E Sadler","year":"2009","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2002-09-2892","article-title":"Von Willebrand disease type 1: a diagnosis in search of a disease","volume":"101","author":"J E Sadler","year":"2003","journal-title":"Blood"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1538-7836.2004.00933.x","article-title":"Slippery criteria for von Willebrand disease type 1","volume":"2","author":"J E Sadler","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"13","key":"ref22","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/bloodadvances.2020002038","article-title":"Low VWF: insights into pathogenesis, diagnosis, and clinical management","volume":"4","author":"J S O'Donnell","year":"2020","journal-title":"Blood Adv"},{"issue":"05","key":"ref23","first-page":"630","article-title":"An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease","volume":"96","author":"A Cumming","year":"2006","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2006-05-020784","article-title":"Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)","volume":"109","author":"A Goodeve","year":"2007","journal-title":"Blood"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study","volume":"109","author":"P D James","year":"2007","journal-title":"Blood"},{"issue":"21","key":"ref26","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood-2017-05-786699","article-title":"Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels","volume":"130","author":"M Lavin","year":"2017","journal-title":"Blood"},{"issue":"20","key":"ref27","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"V H Flood","year":"2016","journal-title":"Blood"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/bloodadvances.2019000992","article-title":"Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy","volume":"4","author":"J C Gill","year":"2020","journal-title":"Blood Adv"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1538-7836.2006.01860.x","article-title":"Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study","volume":"4","author":"P D James","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1538-7836.2006.01823.x","article-title":"Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD","volume":"4","author":"J Eikenboom","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/hae.13881","article-title":"An international survey to inform priorities for new guidelines on von Willebrand disease","volume":"26","author":"M A Kalot","year":"2020","journal-title":"Haemophilia"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/bloodadvances.2021005430","article-title":"von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis","volume":"6","author":"M A Kalot","year":"2022","journal-title":"Blood Adv"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14465","article-title":"The 2021 von Willebrand disease guidelines: clarity and controversy","volume":"28","author":"M Makris","year":"2022","journal-title":"Haemophilia"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/hae.14528","article-title":"Response to \u201cThe 2021 von Willebrand disease guidelines: clarity and controversy\u201d","volume":"28","author":"P D James","year":"2022","journal-title":"Haemophilia"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/jth.14304","article-title":"Genetic regulation of plasma von Willebrand factor levels in health and disease","volume":"16","author":"L L Swystun","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"23","key":"ref36","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1182\/blood.2020009999","article-title":"von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene","volume":"137","author":"B Sadler","year":"2021","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2017.09.025","article-title":"Von Willebrand disease mutation spectrum and associated mutation mechanisms","volume":"159","author":"A de Jong","year":"2017","journal-title":"Thromb Res"},{"issue":"08","key":"ref38","doi-asserted-by":"crossref","first-page":"e0161310","DOI":"10.1371\/journal.pone.0161310","article-title":"Diagnostic value of measuring platelet von Willebrand factor in von Willebrand disease","volume":"11","author":"A Casonato","year":"2016","journal-title":"PLoS One"},{"issue":"14","key":"ref39","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.2021010683","article-title":"Single-cell transcriptional analysis of human endothelial colony-forming cells from patients with low VWF levels","volume":"139","author":"C J Ng","year":"2022","journal-title":"Blood"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.15565","article-title":"von Willebrand factor clearance - biological mechanisms and clinical significance","volume":"183","author":"J M O'Sullivan","year":"2018","journal-title":"Br J Haematol"},{"issue":"09","key":"ref41","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1182\/blood-2011-08-373605","article-title":"Macrophage LRP1 contributes to the clearance of von Willebrand factor","volume":"119","author":"G Rastegarlari","year":"2012","journal-title":"Blood"},{"issue":"09","key":"ref42","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1172\/JCI96400","article-title":"The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity","volume":"128","author":"L L Swystun","year":"2018","journal-title":"J Clin Invest"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1182\/blood-2017-06-787853","article-title":"A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance","volume":"131","author":"S E Ward","year":"2018","journal-title":"Blood"},{"issue":"04","key":"ref44","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3324\/haematol.2017.175216","article-title":"Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor","volume":"103","author":"N Wohner","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2012-09-455089","article-title":"VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease","volume":"121","author":"J Eikenboom","year":"2013","journal-title":"Blood"},{"issue":"19","key":"ref46","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood-2014-09-603241","article-title":"von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease","volume":"125","author":"Y V Sanders","year":"2015","journal-title":"Blood"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2006-04-015065","article-title":"Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival","volume":"108","author":"S L Haberichter","year":"2006","journal-title":"Blood"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood-2007-09-110940","article-title":"Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)","volume":"111","author":"S L Haberichter","year":"2008","journal-title":"Blood"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V99.1.180","article-title":"Reduced von Willebrand factor survival in type Vicenza von Willebrand disease","volume":"99","author":"A Casonato","year":"2002","journal-title":"Blood"},{"issue":"14","key":"ref51","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2018-09-874636","article-title":"Increased galactose expression and enhanced clearance in patients with low von Willebrand factor","volume":"133","author":"S Aguila","year":"2019","journal-title":"Blood"},{"issue":"07","key":"ref52","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/jth.14471","article-title":"von Willebrand factor sialylation - a critical regulator of biological function","volume":"17","author":"S Ward","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1182\/blood-2006-06-032706","article-title":"Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels","volume":"109","author":"C J van Schooten","year":"2007","journal-title":"Blood"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/bloodadvances.2021005118","article-title":"Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations","volume":"6","author":"B Sadler","year":"2022","journal-title":"Blood Adv"},{"issue":"08","key":"ref55","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2018-10-844936","article-title":"How I treat low von Willebrand factor levels","volume":"133","author":"M Lavin","year":"2019","journal-title":"Blood"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/asheducation-2016.1.683","article-title":"New treatment approaches to von Willebrand disease","volume":"2016","author":"M Lavin","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"N T Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/jth.15220","article-title":"Management of elective procedures in low von Willebrand factor patients in the LoVIC study","volume":"19","author":"D Doherty","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref59","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD","volume":"111","author":"G Castaman","year":"2008","journal-title":"Blood"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/jth.13294","article-title":"Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms","volume":"14","author":"S Alb\u00e1nez","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/hae.12664","article-title":"Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease","volume":"21","author":"N Rydz","year":"2015","journal-title":"Haemophilia"},{"issue":"07","key":"ref62","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Y V Sanders","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.15277","article-title":"Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease","volume":"182","author":"F Atiq","year":"2018","journal-title":"Br J Haematol"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjh.15872","article-title":"Advances in understanding the molecular mechanisms that maintain normal haemostasis","volume":"186","author":"J S O'Donnell","year":"2019","journal-title":"Br J Haematol"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/jth.15227","article-title":"Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding","volume":"19","author":"F Atiq","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"19","key":"ref66","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood.2020010038","article-title":"How I treat bleeding disorder of unknown cause","volume":"138","author":"R I Baker","year":"2021","journal-title":"Blood"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1980-8198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T18:31:47Z","timestamp":1676917907000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1980-8198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":65,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,2,20]]},"published-print":{"date-parts":[[2023,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1980-8198","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}